

Valentine Karen
Form 4
July 17, 2009

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Valentine Karen

(Last) (First) (Middle)

C/O ANTIGENICS INC., 3
FORBES RD

(Street)

LEXINGTON, MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANTIGENICS INC /DE/ [AGEN]

3. Date of Earliest Transaction
(Month/Day/Year)
07/15/2009

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
VP and General Counsel

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	07/14/2009		A ⁽¹⁾	V 67,300 A \$1	101,974	D	
Common Stock	07/15/2009		S ⁽²⁾	7,753 D \$1.763	94,221	D	
Common Stock	07/16/2009		S ⁽²⁾	15,930 D \$1.618	78,291	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474 (9-02)

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)			
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of	
Stock Option, right to buy	\$ 10.17	07/16/2009		J ⁽³⁾		15,000	<u>(3)</u>	07/16/2009	Common Stock	1
Stock Option, right to buy	\$ 6.3	07/16/2009		J ⁽³⁾		7,500	<u>(3)</u>	07/16/2009	Common Stock	7
Stock Option, right to buy	\$ 4.76	07/16/2009		J ⁽³⁾		7,500	<u>(3)</u>	07/16/2009	Common Stock	7
Stock Option, right to buy	\$ 5.13	07/16/2009		J ⁽³⁾		7,500	<u>(3)</u>	07/16/2009	Common Stock	7
Stock Option, right to buy	\$ 1.58	07/16/2009		A		28,125	10/16/2009 ⁽⁴⁾	07/16/2019	Common Stock	2

Reporting Owners

Reporting Owner Name / Address	Relationships
Valentine Karen C/O ANTIGENICS INC. 3 FORBES RD LEXINGTON, MA 02421	Director 10% Owner Officer VP and General Counsel

Signatures

Christine M. Klaskin, by Power of
Attorney

07/17/2009

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents settlement of restricted stock which was granted on January 14, 2009 in lieu of an annual cash bonus for 2008 performance.
- (2) Represents exclusively, shares sold to cover minimum federal, state and local tax withholding requirements upon the vesting of the restricted shares granted in lieu of a cash bonus for 2008 performance.
- (3) Options cancelled pursuant to the terms of the offer by Antigenics Inc. to exchange certain outstanding options granted under the Antigenics 1999 Equity Incentive Plan, as amended for options to be granted under the 2009 Equity Incentive Plan.
- (4) Options vest in 6 equal quarterly installments over an 18 month period beginning October 16, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.